Metabolic effects of olanzapine in patients with newly diagnosed psychosis

Emilio Fernandez-Egea, Brian J Miller, Clemente Garcia-Rizo, Miguel Bernardo, Brian Kirkpatrick

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Patients with newly diagnosed psychosis (n = 30) were enrolled in a 16-week open trial of olanzapine. Body mass index, fasting glucose, hemoglobin A1c, fasting insulin, IL-6, and a fasting lipid profile were measured at baseline and at 4-week intervals. There was a significant, linear increase over time in fasting glucose (P = 0.043), weight (P < 0.001), body mass index (P < 0.001), total cholesterol (P = 0.005), triglycerides (P = 0.003), and low-density lipoprotein (P = 0.013), but not hemoglobin A1c (P = 0.691), fasting insulin (P = 0.690), IL-6 (P = 0.877), or high-density lipoprotein (P = 0.446). An abnormal baseline IL-6 was a significant predictor of a greater increase in both total cholesterol (P < 0.01) and low-density lipoprotein (P < 0.01). Otherwise, neither parental history of type 2 diabetes mellitus nor baseline IL-6 predicted changes in metabolic measures. Changes in metabolic measures with olanzapine treatment can be detected early in the treatment of patients who are previously antipsychotic naive. The absence of a change in fasting insulin suggests a failure of pancreatic islet cells to compensate for the increase in fasting glucose.

Original languageEnglish (US)
Pages (from-to)154-159
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume31
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

olanzapine
Psychotic Disorders
Fasting
Interleukin-6
Antipsychotic Agents
Insulin
Islets of Langerhans
LDL Lipoproteins
Glucose
Type 2 Diabetes Mellitus
Body Mass Index
Cholesterol
HDL Lipoproteins
Schizophrenia
Hemoglobins
Triglycerides

Keywords

  • diabetes
  • family history
  • olanzapine
  • psychosis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Metabolic effects of olanzapine in patients with newly diagnosed psychosis. / Fernandez-Egea, Emilio; Miller, Brian J; Garcia-Rizo, Clemente; Bernardo, Miguel; Kirkpatrick, Brian.

In: Journal of Clinical Psychopharmacology, Vol. 31, No. 2, 01.04.2011, p. 154-159.

Research output: Contribution to journalArticle

Fernandez-Egea, Emilio ; Miller, Brian J ; Garcia-Rizo, Clemente ; Bernardo, Miguel ; Kirkpatrick, Brian. / Metabolic effects of olanzapine in patients with newly diagnosed psychosis. In: Journal of Clinical Psychopharmacology. 2011 ; Vol. 31, No. 2. pp. 154-159.
@article{20acffcdc9c24c17a04c0eef9d1a10db,
title = "Metabolic effects of olanzapine in patients with newly diagnosed psychosis",
abstract = "Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Patients with newly diagnosed psychosis (n = 30) were enrolled in a 16-week open trial of olanzapine. Body mass index, fasting glucose, hemoglobin A1c, fasting insulin, IL-6, and a fasting lipid profile were measured at baseline and at 4-week intervals. There was a significant, linear increase over time in fasting glucose (P = 0.043), weight (P < 0.001), body mass index (P < 0.001), total cholesterol (P = 0.005), triglycerides (P = 0.003), and low-density lipoprotein (P = 0.013), but not hemoglobin A1c (P = 0.691), fasting insulin (P = 0.690), IL-6 (P = 0.877), or high-density lipoprotein (P = 0.446). An abnormal baseline IL-6 was a significant predictor of a greater increase in both total cholesterol (P < 0.01) and low-density lipoprotein (P < 0.01). Otherwise, neither parental history of type 2 diabetes mellitus nor baseline IL-6 predicted changes in metabolic measures. Changes in metabolic measures with olanzapine treatment can be detected early in the treatment of patients who are previously antipsychotic naive. The absence of a change in fasting insulin suggests a failure of pancreatic islet cells to compensate for the increase in fasting glucose.",
keywords = "diabetes, family history, olanzapine, psychosis",
author = "Emilio Fernandez-Egea and Miller, {Brian J} and Clemente Garcia-Rizo and Miguel Bernardo and Brian Kirkpatrick",
year = "2011",
month = "4",
day = "1",
doi = "10.1097/JCP.0b013e31820fcea3",
language = "English (US)",
volume = "31",
pages = "154--159",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Metabolic effects of olanzapine in patients with newly diagnosed psychosis

AU - Fernandez-Egea, Emilio

AU - Miller, Brian J

AU - Garcia-Rizo, Clemente

AU - Bernardo, Miguel

AU - Kirkpatrick, Brian

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Patients with newly diagnosed psychosis (n = 30) were enrolled in a 16-week open trial of olanzapine. Body mass index, fasting glucose, hemoglobin A1c, fasting insulin, IL-6, and a fasting lipid profile were measured at baseline and at 4-week intervals. There was a significant, linear increase over time in fasting glucose (P = 0.043), weight (P < 0.001), body mass index (P < 0.001), total cholesterol (P = 0.005), triglycerides (P = 0.003), and low-density lipoprotein (P = 0.013), but not hemoglobin A1c (P = 0.691), fasting insulin (P = 0.690), IL-6 (P = 0.877), or high-density lipoprotein (P = 0.446). An abnormal baseline IL-6 was a significant predictor of a greater increase in both total cholesterol (P < 0.01) and low-density lipoprotein (P < 0.01). Otherwise, neither parental history of type 2 diabetes mellitus nor baseline IL-6 predicted changes in metabolic measures. Changes in metabolic measures with olanzapine treatment can be detected early in the treatment of patients who are previously antipsychotic naive. The absence of a change in fasting insulin suggests a failure of pancreatic islet cells to compensate for the increase in fasting glucose.

AB - Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Patients with newly diagnosed psychosis (n = 30) were enrolled in a 16-week open trial of olanzapine. Body mass index, fasting glucose, hemoglobin A1c, fasting insulin, IL-6, and a fasting lipid profile were measured at baseline and at 4-week intervals. There was a significant, linear increase over time in fasting glucose (P = 0.043), weight (P < 0.001), body mass index (P < 0.001), total cholesterol (P = 0.005), triglycerides (P = 0.003), and low-density lipoprotein (P = 0.013), but not hemoglobin A1c (P = 0.691), fasting insulin (P = 0.690), IL-6 (P = 0.877), or high-density lipoprotein (P = 0.446). An abnormal baseline IL-6 was a significant predictor of a greater increase in both total cholesterol (P < 0.01) and low-density lipoprotein (P < 0.01). Otherwise, neither parental history of type 2 diabetes mellitus nor baseline IL-6 predicted changes in metabolic measures. Changes in metabolic measures with olanzapine treatment can be detected early in the treatment of patients who are previously antipsychotic naive. The absence of a change in fasting insulin suggests a failure of pancreatic islet cells to compensate for the increase in fasting glucose.

KW - diabetes

KW - family history

KW - olanzapine

KW - psychosis

UR - http://www.scopus.com/inward/record.url?scp=79952441523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952441523&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e31820fcea3

DO - 10.1097/JCP.0b013e31820fcea3

M3 - Article

C2 - 21346617

AN - SCOPUS:79952441523

VL - 31

SP - 154

EP - 159

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -